Document is current
Any future updates will be listed below
-
Authors
Kim, Sarah H.
Da Cruz Paula, Arnaud
Basili, Thais https://orcid.org/0000-0003-3216-3544
Dopeso, Higinio https://orcid.org/0000-0003-0060-1861
Bi, Rui
Pareja, Fresia
da Silva, Edaise M. https://orcid.org/0000-0003-3281-7333
Gularte-Mérida, Rodrigo https://orcid.org/0000-0002-4383-2523
Sun, Zhen https://orcid.org/0000-0001-9515-1925
Fujisawa, Sho https://orcid.org/0000-0002-5872-5624
Smith, Caitlin G.
Ferrando, Lorenzo https://orcid.org/0000-0002-4025-7930
Martins Sebastião, Ana Paula
Bykov, Yonina
Li, Anqi
Silveira, Catarina https://orcid.org/0000-0002-4693-1316
Ashley, Charles W.
Stylianou, Anthe
Selenica, Pier
Samore, Wesley R.
Jungbluth, Achim A.
Zamarin, Dmitriy
Abu-Rustum, Nadeem R.
Helin, Kristian https://orcid.org/0000-0003-1975-6097
Soslow, Robert A.
Reis-Filho, Jorge S. https://orcid.org/0000-0003-2969-3173
Oliva, Esther
Weigelt, Britta
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA008748)
- License Information
-
More Information
Article History
Received: 15 May 2019
Accepted: 26 November 2019
First Online: 2 January 2020
Competing interests
: D.Z. reports consulting fees from Merck, Synlogic Therapeutics, Tizona Therapeutics, and Tesaro, outside the submitted work. D.Z. has a patent for use of Newcastle Disease Virus for cancer therapy, outside the submitted work. J.S. Reis-Filho reports personal/consultancy fees from VolitionRx, Page.AI, Invicro, Roche, Genentech, Ventana, Goldman Sachs and REPARE Therapeutics, outside the submitted work. The remaining authors declare no competing interests.
